newsfilter
← Latest News
GlobeNewswire·

NGM Bio Provides Business Highlights and Reports First Quarter 2022 Financial Results

Initiated Phase 1/1b clinical trial of NGM831, an ILT3 antagonist antibody product candidate, as a monotherapy and in combination with KEYTRUDA® (pembrolizumab), for the treatment of patients with advanced solid tumors Presented preclinical research f